'Painful' regulations keeping Google on the periphery of life sciences; Catalent lines up for an IPO worth $100M--or much more;

Biotech IT News

> 'Painful' regulations keeping Google on the periphery of life sciences. Story

> Venter hires Google machine learning expert to build Translate for genomics. Article

> Buzz: Google Ventures leading $100M round in oncology Big Data platform. More

> Google joins genomics alliance as it prepares industry-focused cloud services. Report

> Medidata stung by $4.8M wire transfer fraud. Item

CRO News

> Catalent lines up for an IPO worth $100M--or much more. Article

> Big Pharma megadeals could spell trouble for CROs. Story

> Report: Indian clinical trials fell 93% last year. More

> Catalent shoots for $872M in a blockbuster IPO. Report

> InVentiv signs on to market 3-D printed drugs. Item

Animal Health News

> Will Zoetis stand alone when Big Pharma's music stops? More

> Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal. Article

> FierceAnimalHealth: Bringing a unique approach to the animal health industry. Editor's Corner

> Five questions for Aratana CEO Steven St. Peter. Editor's Corner

> Merck releases tilapia vaccine. Story

Biotech Research News

> The top 10 biomedical research institutions. Special Report

> Top 15 NIH-funded disease areas. Special Report

> 10 drugs that could stop Ebola. Special Report

> Notable academic-pharma alliances of 2014. Special Report

> Diabetes culprit may be a single enzyme. Article

PharmaManufacturing News

> Teva recalling more than 1M bottles of generic Cymbalta. Article

> Saline shortage: FDA works with Baxter, Hospira and Braun. Report

> Sun Pharma plant joins the FDA list of banned Indian facilities. Story

> FDA says Apotex India plant has faked data for years. More

> Merck again shipping BCG cancer treatment but Sanofi still is not. Item

Drug Delivery News

> MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Report

> Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate.' Story

> AstraZeneca looks to pen injector approval to turn Bydureon diabetes sales around. Article

> Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. More

> Roche's delivery method 'shuttles' Alzheimer's drugs past the blood-brain barrier. Item

Diagnostics News

> Illumina, AstraZeneca, Janssen and Sanofi to pursue universal companion Dx test. Article

> GE Healthcare's Dineen: A quest for new acquisitions will continue. Report

> J. Craig Venter raises $70M for a gene-sequencing and therapeutic startup. Story

> British startup finishes quick and easy Ebola test. Item

> GE Healthcare, FBI allege Chinese engineer stole MRI trade secrets. More

Pharma Marketing News

> The top 10 pharma companies in social media. Special Report

> 10 big brands keep pumping out big bucks, with a little help from price hikes. Article

> Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story

> Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C. More

> BMS sues ex-account manager, claiming she took PD-1 marketing secrets to Merck agency. Item

Vaccines News

> CDC warns H1N1 virus is causing severe flu in young adults. Article

> Agenus' genital herpes vax cuts viral load 75% in PhII. Story

> Buzz: Merck and Novartis trying to iron out details of business unit swap. Report

> Top 10 best-selling vaccines of 2013. Special Report

> Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. More

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.